Edgewise Therapeutics, Inc. (EWTX) Spending and interest coverage
- R&D / revenue · 12 months: Value (m); Formula and calculation Research and development expense / revenue. Period ending 2026-06-30..
- Stock-based compensation / revenue · 12 months: Value (m); Formula and calculation Share-based compensation / revenue. Period ending 2026-06-30..
- Interest coverage · 12 months: Value (m); Formula and calculation Estimated: average term debt × dated USD coupon proxy + average commercial paper × matching-currency disclosed rate at or before period end. Swaps, foreign-exchange, lease interest and amortization are not quantified..
Spending and interest coverage
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| R&D / revenue · 12 months | (m) | Research and development expense / revenue. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
| Stock-based compensation / revenue · 12 months | (m) | Share-based compensation / revenue. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
| Interest coverage · 12 months | (m) | Estimated: average term debt × dated USD coupon proxy + average commercial paper × matching-currency disclosed rate at or before period end. Swaps, foreign-exchange, lease interest and amortization are not quantified. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Research and development spending | 171.27M USD | Research and Development Expense |
| Revenue | (m) | |
| Stock-based compensation | 36.04M USD | Share-based Payment Arrangement, Noncash Expense |
| Operating income | -218.90M USD | Operating Income (Loss) |
| Interest expense · reported / estimated | (m) | · Estimated expense assumptions |
Latest interest expense basis: (m). Estimated values carry *; expand each history row’s basis for its dated balances and rate assumptions.
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Research and development spending (USD) | Revenue (USD) | Stock-based compensation (USD) | Operating income (USD) | Interest expense · reported / estimated (USD) | R&D / revenue | SBC / revenue | Interest coverage | Interest expense basis |
|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $171.27M | (m) | $36.04M | $-218.90M | (m) | (m) | (m) | (m) | (m) |
| 2026-03-31 | $157.28M | (m) | $34.41M | $-199.56M | (m) | (m) | (m) | (m) | (m) |
| 2025-12-31 | $151.39M | (m) | $34.75M | $-191.41M | (m) | (m) | (m) | (m) | (m) |
| 2025-09-30 | $144.16M | (m) | $32.61M | $-180.97M | (m) | (m) | (m) | (m) | (m) |
| 2025-06-30 | $138.91M | (m) | $31.41M | $-174.54M | (m) | (m) | (m) | (m) | (m) |
| 2025-03-31 | $136.03M | (m) | $28.90M | $-170.04M | (m) | (m) | (m) | (m) | (m) |
| 2024-12-31 | $126.97M | (m) | $24.71M | $-158.83M | (m) | (m) | (m) | (m) | (m) |
| 2024-09-30 | $118.28M | (m) | $22.13M | $-147.15M | (m) | (m) | (m) | (m) | (m) |
| 2024-06-30 | $109.84M | (m) | $19.81M | $-136.17M | (m) | (m) | (m) | (m) | (m) |
| 2024-03-31 | $98.72M | (m) | $18.59M | $-123.41M | (m) | (m) | (m) | (m) | (m) |
| 2023-12-31 | $90.91M | (m) | $17.56M | $-114.36M | (m) | (m) | (m) | (m) | (m) |
| 2023-09-30 | $79.83M | (m) | $16.14M | $-102.57M | (m) | (m) | (m) | (m) | (m) |
| 2023-06-30 | $69.94M | (m) | $14.76M | $-91.38M | (m) | (m) | (m) | (m) | (m) |
| 2023-03-31 | $62.78M | (m) | $12.78M | $-82.54M | (m) | (m) | (m) | (m) | (m) |
| 2022-12-31 | $54.03M | (m) | $10.92M | $-71.66M | (m) | (m) | (m) | (m) | (m) |
| 2022-09-30 | $46.51M | (m) | $9.06M | $-62.40M | (m) | (m) | (m) | (m) | (m) |
| 2022-06-30 | $42.49M | (m) | $7.44M | $-57.22M | (m) | (m) | (m) | (m) | (m) |
| 2022-03-31 | $37.95M | (m) | $6.09M | $-51.18M | (m) | (m) | (m) | (m) | (m) |
| 2021-12-31 | $32.19M | (m) | $4.40M | $-43.22M | (m) | (m) | (m) | (m) | (m) |
| 2021-09-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2021-06-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2021-03-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2020-12-31 | $14.98M | (m) | $354.00K | $-17.19M | (m) | (m) | (m) | (m) | (m) |
| 2020-09-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2020-06-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2020-03-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Viking Therapeutics, Inc. (VKTX) | United States | $4.287B | -8.51 |
| Indivior Pharmaceuticals, Inc. (INDV) | $4.250B | 14.09 | |
| Tango Therapeutics, Inc. (TNGX) | United States | $4.154B | -42.53 |
| Veradermics, Inc (MANE) | United States | $4.839B | |
| AbCellera Biologics Inc. (ABCL) | $3.879B | -14.59 | |
| Erasca, Inc. (ERAS) | United States | $5.073B | -19.96 |
| Dianthus Therapeutics, Inc. /DE/ (DNTH) | United States | $5.082B | -27.79 |
| ACADIA PHARMACEUTICALS INC (ACAD) | United States | $3.823B | 11.45 |
| PTC THERAPEUTICS, INC. (PTCT) | United States | $5.199B | -177.07 |
| Xenon Pharmaceuticals Inc. (XENE) | $3.684B | -14.27 |